Abstract
Clopidogrel is an antiplatelet drug commonly used to inhibit platelet aggregation after acute coronary events and interventions. It is a prodrug that requires CYP2C19-mediated metabolism to its active metabolite. Patients with genetic deficiency or low enzyme activity of CYP2C19 would experience reduced effectiveness of clopidogrel, and in these patients alternative antiplatelet therapy should be considered.1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
